|Table of Contents|

Research progress of immunotherapy for microsatellite instability gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 02
Page:
316-320
Research Field:
Publishing date:

Info

Title:
Research progress of immunotherapy for microsatellite instability gastric cancer
Author(s):
ZHANG Xin1; FANG Changxing2; YANG Min3; YAO Tian4; JIA Kai4; GUO Jiansheng4
1.The First Clinical Medical College of Shanxi Medical University,Shanxi Taiyuan 030001,China；2.College of Medical Imaging,Shanxi Medical University,Shanxi Taiyuan 030001,China；3.Department of Colorectal Anal Surgery,Shanxi Provincial People's Hospital,Shanxi Taiyuan 030012,China；4.Department of Gastrointestinal Surgery,the First Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China.
Keywords:
gastric cancer; microsatellite instability; mismatch repair defects; immunotherapy; prognosis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2025.02.023
Abstract:
The microsatellite instability (MSI) gastric cancer is a specific type of gastric cancer that accounts for about 22% of total cases.Microsatellites are regions of the genome with short tandem repeats,and stability refers to the fact that these sequences remain unchanged during cell division and DNA replication.In MSI type gastric cancer,this instability is usually caused by mutation or inactivation of DNA mismatch repair genes (such as MLH1,MSH2,MSH6,etc.),resulting in reduced DNA repair capacity,resulting in a large number of microsatellite sequence variations and mutations in the genome of the tumor cells.Although the incidence of MSI type gastric cancer is relatively low,it has been shown in multiple studies to show good therapeutic effect on immunotherapy,and is widely recognized as a predictor of good prognosis.This article comprehensively summarizes and reviews the research status of immunotherapy-based comprehensive treatment for MSI type gastric cancer patients,aiming to provide more reliable evidence for clinical treatment of this type of patients.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
[2] HAN B,ZHENG R,ZENG H,et al.Cancer incidence and mortality in China,2022［J］.Journal of the National Cancer Center,2024,4(1):47-53.
[3] ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health,2018,6(5):e555-e567.
[4] ADAM JB.Comprehensive molecular characterization of gastric adenocarcinoma［J］.Nature，2014，513（7517）：202-209.
[5] VIKAS P,MESSERSMITH H,COMPTON C,et al.Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy:ASCO endorsement of college of american pathologists guideline［J］.J Clin Oncol,2023,41(10):1943-1948.
[6] RATOVOMANANA T,COHEN R,SVRCEK M,et al.Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair［J］.Gastroenterology,2021,161(3):814-826.
[7] KASI PM,BUCHEIT LA,LIAO J,et al.Pan-cancer prevalence of microsatellite instability-high (MSI-H) identified by circulating tumor DNA and associated real-world clinical outcomes［J］.JCO Precis Oncol,2023,7:e2300118.
[8] LI JH,ZHANG DY,ZHU JM,et al.Clinical applications and perspectives of circulating tumor DNA in gastric cancer［J］.Cancer Cell Int,2024,24(1):13.
[9] GRIZZI G,SALATI M,BONOMI M,et al.Circulating tumor DNA in gastric adenocarcinoma:future clinical applications and perspectives［J］.Int J Mol Sci,2023,24(11):9421.
[10] AL ZOUGHBI W,FOX J,BEG S,et al.Validation of a circulating tumor DNA-based next-generation sequencing assay in a cohort of patients with solid tumors:a proposed solution for decentralized plasma testing［J］.Oncologist,2021,26(11):e1971-e1981.
[11] NAKAMURA Y,KAWAZOE A,LORDICK F,et al.Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers:an emerging paradigm［J］.Nat Rev Clin Oncol,2021,18(8):473-487.
[12] KUMAR A,GREEN M,THACKER J,et al.Circulating tumor DNA testing overcomes limitations of comprehensive genomic profiling from tumor tissue［J］.Case Rep Oncol,2023,16(1):210-217.
[13] SILVEIRA AB,BIDARD FC,KASPEREK A,et al.High-accuracy determination of microsatellite instability compatible with liquid biopsies［J］.Clin Chem,2020,66(4):606-613.
[14] CECCON C,ANGERILLI V,RASOLA C,et al.Microsatellite instable colorectal adenocarcinoma diagnostics:the advent of liquid biopsy approaches［J］.Front Oncol,2022,12:930108.
[15] JANAVICIUS R,MATIUKAITE D,JAKUBAUSKAS A,et al.Microsatellite instability detection by high-resolution melting analysis［J］.Clin Chem,2010,56(11):1750-1757.
[16] TANABE H,MIZUKAMI Y,TAKEI H,et al.Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteria［J］.J Pathol Clin Res,2021,7(4):397-409.
[17] ESO Y,SHIMIZU T,TAKEDA H,et al.Microsatellite instability and immune checkpoint inhibitors:toward precision medicine against gastrointestinal and hepatobiliary cancers［J］.J Gastroenterol,2020,55(1):15-26.
[18] KIM DG,AN JY,KIM H,et al.Clinical implications of microsatellite instability in early gastric cancer［J］.J Gastric Cancer,2019,19(4):427-437.
[19] 李丹,李小芹,王德强,等.环境暴露和错配修复基因多态性单独及联合在胃癌家族性聚集中的作用［D］.镇江:江苏大学,2017:1-54. LI D,LI XQ,WANG DQ,et al.Role of environmental exposure and mismatch repair gene polymorphisms alone and in combination in familial aggregation of gastric cancer［D］.Zhenjiang:Jiangsu University,2017:1-54.
[20] ANDRE T,SHIU KK,KIM TW,et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer［J］.N Engl J Med,2020,383(23):2207-2218.
[21] OVERMAN MJ,LONARDI S,WONG KYM,et al.Durable clinical beneft with nivolumab plus ipilimumab in DNA mismatch repair-defcient/microsatellite instability-high metastatic colorectal cancer［J］.J Clin Oncol,2018,36(8):773-779.
[22] LENZ HJ,VAN CUTSEM E,LUISA LIMON M,et al.First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repairdefcient metastatic colorectal cancer:the phase II CheckMate 142 study［J］.J Clin Oncol,2022,40(2):161-170.
[23] LE DT,DURHAM JN,SMITH KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］.Science,2017,357(6349):409-413.
[24] MURO K,CHUNG HC,SHANKARAN V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012):a multicenter，open-label，phase 1b trial［J］.Lancet Oncol,2016,17(6):717-726.
[25] SHITARA K,CUTSEM EV,BANG YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with flrst-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial［J］.JAMA Oncol,2020,6(10):1571-1580.
[26] JANJIGIAN YY,SHITARA K,MOEHLER M,et al.First-line Nivolumab plus chemotherapy versuschemotherapy alone for advanced gastric,gastrooesophageal junction,and oesophageal adenocarcinoma (CheckMate 649):a randomised,open-label,phase 3 trial［J］.Lancet,2021,398(10294):27-40.
[27] AL-BATRAN SE，LORENZEN S，HOMANN N，et al.1429P pathological regression in patients with microsatellite instability(MSI)receiving perioperative atezolizumab in combination with FLOT vs.FLOT alone for resectable esophagogastric adenocarcinoma:Results from the DANTE trial of the German Gastric Group at the AIO and SAKK［J］.Ann Oncol，2021，32(suppl 5):1069.
[28] ANDRE T,TOUGERON D,PIESSEN G,et al.Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma:The GERCOR NEONIPIGA phase II study［J］.J Clin Oncol,2023,41(2):255-265.
[29] 李国新.胃癌微创外科研究新进展［J］.中华消化外科杂志,2023,22(3):326-331. LI GX.New advances in minimally invasive surgery for gastric cancer［J］.Chinese Journal of Digestive Surgery,2023,22(3):326-331.
[30] PIETRANTONIO F,RAIMONDI A,LONARDI S,et al.INFINITY: A multicentre,single-arm,multi-cohort,phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)［R］.American Society of Clinical Oncology (ASCO),2023,41(4_suppl):358.
[31] PULIGA E,CORSO S,PIETRANTONIO F,et al.Microsatellite instability in gastric cancer:Between lights and shadows［J］.Cancer Treat Rev,2021,95:102175.
[32] KOHLRUSS M,OTT K,GROSSER B,et al.Sexual difference matters:females with high microsatellite instability show increased survival after neoadjuvant chemotherapy in gastric cancer［J］.Cancers (Basel),2021,13(5):1048.
[33] ZEPEDA-NAJAR C,PALACIOS-ASTUDILLO RX,CHAVEZ-HERNANDEZ JD,et al.Prognostic impact of microsatellite instability in gastric cancer［J］.Contemp Oncol (Pozn),2021,25(1):68-71.
[34] HASHIMOTO T,KUROKAWA Y,TAKAHASHI T,et al.Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer［J］.Gastric Cancer,2019,22(4):785-792.
[35] 孟令桦,吴海涛,梁婷婷,等.微卫星不稳定性在胃癌预后及疗效预测中的意义［J］.肿瘤研究与临床,2020,32(03)：213-216. MENG LH,WU HT,LIANG TT,et al.The significance of microsatellite instability in the prediction of prognosis and efficacy of gastric cancer［J］.Cancer Research and Clinic,2020,32(03) :213-216.
[36] ZHANG Z,HUANG J,LI Y,et al.Global burden,risk factors,clinicopathological characteristics,molecular biomarkers and outcomes of microsatellite instability-high gastric cancer［J］.Aging (Albany NY),2024,16(1):948-963.
[37] LI X,ZHANG L,WANG C,et al.Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics［J］.J Gastrointest Oncol,2021,12(6):2719-2727.
[38] TALARI FF,BOZORG A,ZEINALI S,et al.Low incidence of microsatellite instability in gastric cancers and its association with the clinicopathological characteristics:a comparative study［J］.Sci Rep,2023,13(1):21743.
[39] CRISTESCU R,LEE J,NEBOZHYN M,et al.Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes［J］.Nat Med,2015,21(5):449-456.
[40] MARRELLI D,POLOM K,PASCALE V,et al.Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer［J］.Ann Surg Oncol,2016,23(3):943-950.
[41] BERMUDEZ A,ARRANZ-SALAS I,MERCADO S,et al.Her2-positive and microsatellite instability status in gastric cancer-clinicopathological implications［J］.Diagnostics (Basel),2021,11(6):944.

Memo

Memo:
山西省自然科学基金（编号：202203021211026）；山西医科大学第一医院院基金（编号：YY2203）
Last Update: 1900-01-01